FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2555363527> ?p ?o ?g. }

• W2555363527 abstract "Abstract Abstract 4292 High-dose chemotherapy with autologous HSCT results in profound immunodeficiency early post transplant. Immune reconstitution is largely derived from the transplanted stem cells and occurs over a period of many months. Sex steroid hormones (testosterone and estrogen) have been shown to inhibit thymic function. Castration and sex steroid inhibition have been reported to stimulate thymic regeneration and production of T-cells and also, improved bone marrow function. We performed a study to test the hypothesis that temporarily blocking production of sex hormones using leuprolide acetate, a gonadotropin hormone-releasing hormone [GnRH] agonist, would improve thymic function and accelerate immune reconstitution following autologous stem cell transplantation. Methods: Adult patients receiving myeloablative autologous peripheral blood progenitor cell transplantation for lymphoma, Hodgkin's disease or multiple myeloma were eligible. Females and males, age 18–50 and 18–65 years, respectively, were included. Patients were required to be in remission or have chemosensitive relapse. Patients could not have received mediastinal radiation, or recent testosterone or estrogen treatment, or post transplant therapy that would affect immune function. Patients were randomized to receive 3 intramuscular injections of leuprolide acetate (Lupron 11.25 mg 3 Month Depot) or placebo approximately 3 months apart to cover the period from the date of transplantation to 8 months post HSCT. The primary endpoint was in vitro antibody and T cell response to vaccination with keyhole limpet haemocyanin (KLH) at 6 months post-HSCT. Immunoglobulins were measured by ELISA and interferon-gamma (IFNγ) by ELISpot. Results: 25 subjects (19 males and 6 females) were enrolled into the study at 3 sites. 13 were randomized to placebo and 12 to leuprolide treatment. As expected, suppression of luteinizing hormone and total testosterone was observed in males in the leuprolide acetate group at all evaluation time points during treatment (P<0.1 vs. placebo). There was no significant difference in time to engraftment or in the adverse events and transplant related toxicities experienced by the leuprolide or the placebo group. One subject in the leuprolide acetate group died during the study due to pneumonia after hematopoietic recovery, which was not considered related to study drug. Early disease progression occurred in one patient in the leuprolide acetate and 3 in the placebo group. The study was closed due to slow patient accrual. 9 patients in each group completed 6 months on study. 8 patients in the leuprolide group and 5 in the placebo group received KLH vaccination and were evaluable for response one month later. There were significantly improved IgM and IgG1 responses in the leuprolide group; no significant difference was detected for IgG2, IgG3, IgG4 and IFNγ responses. The following table shows the difference in the assays performed prevaccination and 1 month post vaccination. The output of naïve T-cell subsets and the production of TCR rearrangement excision circles (TRECs) were determined at screening, and post HSCT. There was an increase in naïve CD4+ TREC positive cells at the 6 month time point consistent with renewed thymus function. Conclusion: Despite the limited number of patients, there was a trend to increased antibody responses to the de novo antigen KLH, which reached statistical significance for IgM and IgG1, reflecting increased primary and secondary immune responses. Another indicator of thymus function was the appearance of circulating naïve, TREC+ CD4+ cells at 6 months in the leuprolide acetate group. Further study of sex steroid inhibition is needed to fully establish the enhanced thymic function and immune reconstitution following HSCT. Disclosures: Off Label Use: Leuprolide (Lupron) to enhance immune recovery after stem cell transplantation. Jiang:Abbott: Employment, Equity Ownership. Chwalisz:Abbott: Employment, Equity Ownership. Mattia-Goldberg:Abbott: Employment, Equity Ownership. Sajwani:Abbott: Employment, Equity Ownership. Boyd:Norwood Immunology: Employment." @default.
• W2555363527 created "2016-11-30" @default.
• W2555363527 creator A5002347804 @default.
• W2555363527 creator A5019128517 @default.
• W2555363527 creator A5021739652 @default.
• W2555363527 creator A5036816774 @default.
• W2555363527 creator A5045306382 @default.
• W2555363527 creator A5048317694 @default.
• W2555363527 creator A5048913229 @default.
• W2555363527 creator A5056495325 @default.
• W2555363527 creator A5058261682 @default.
• W2555363527 creator A5063182955 @default.
• W2555363527 creator A5069368596 @default.
• W2555363527 creator A5082932039 @default.
• W2555363527 creator A5088324465 @default.
• W2555363527 date "2010-11-19" @default.
• W2555363527 modified "2023-09-26" @default.
• W2555363527 title "Leuprolide Acetate (GnRH Agonist) to Enhance Immune Function Post-Autologous Hematopoietic Stem Cell Transplantation (HSCT)" @default.
• W2555363527 doi "https://doi.org/10.1182/blood.v116.21.4292.4292" @default.
• W2555363527 hasPublicationYear "2010" @default.
• W2555363527 type Work @default.
• W2555363527 sameAs 2555363527 @default.
• W2555363527 citedByCount "0" @default.
• W2555363527 crossrefType "journal-article" @default.
• W2555363527 hasAuthorship W2555363527A5002347804 @default.
• W2555363527 hasAuthorship W2555363527A5019128517 @default.
• W2555363527 hasAuthorship W2555363527A5021739652 @default.
• W2555363527 hasAuthorship W2555363527A5036816774 @default.
• W2555363527 hasAuthorship W2555363527A5045306382 @default.
• W2555363527 hasAuthorship W2555363527A5048317694 @default.
• W2555363527 hasAuthorship W2555363527A5048913229 @default.
• W2555363527 hasAuthorship W2555363527A5056495325 @default.
• W2555363527 hasAuthorship W2555363527A5058261682 @default.
• W2555363527 hasAuthorship W2555363527A5063182955 @default.
• W2555363527 hasAuthorship W2555363527A5069368596 @default.
• W2555363527 hasAuthorship W2555363527A5082932039 @default.
• W2555363527 hasAuthorship W2555363527A5088324465 @default.
• W2555363527 hasConcept C126322002 @default.
• W2555363527 hasConcept C134018914 @default.
• W2555363527 hasConcept C2777408962 @default.
• W2555363527 hasConcept C2911091166 @default.
• W2555363527 hasConcept C71924100 @default.
• W2555363527 hasConceptScore W2555363527C126322002 @default.
• W2555363527 hasConceptScore W2555363527C134018914 @default.
• W2555363527 hasConceptScore W2555363527C2777408962 @default.
• W2555363527 hasConceptScore W2555363527C2911091166 @default.
• W2555363527 hasConceptScore W2555363527C71924100 @default.
• W2555363527 hasLocation W25553635271 @default.
• W2555363527 hasOpenAccess W2555363527 @default.
• W2555363527 hasPrimaryLocation W25553635271 @default.
• W2555363527 hasRelatedWork W1991221997 @default.
• W2555363527 hasRelatedWork W2066643781 @default.
• W2555363527 hasRelatedWork W2068932869 @default.
• W2555363527 hasRelatedWork W2286855285 @default.
• W2555363527 hasRelatedWork W2352512052 @default.
• W2555363527 hasRelatedWork W2384490000 @default.
• W2555363527 hasRelatedWork W2419514399 @default.
• W2555363527 hasRelatedWork W2461019365 @default.
• W2555363527 hasRelatedWork W2528967355 @default.
• W2555363527 hasRelatedWork W2557751379 @default.
• W2555363527 hasRelatedWork W2557900081 @default.
• W2555363527 hasRelatedWork W2558236004 @default.
• W2555363527 hasRelatedWork W2566992089 @default.
• W2555363527 hasRelatedWork W2570303732 @default.
• W2555363527 hasRelatedWork W2572284537 @default.
• W2555363527 hasRelatedWork W2581751864 @default.
• W2555363527 hasRelatedWork W2592202132 @default.
• W2555363527 hasRelatedWork W2979292486 @default.
• W2555363527 hasRelatedWork W2980052686 @default.
• W2555363527 hasRelatedWork W2980166712 @default.
• W2555363527 isParatext "false" @default.
• W2555363527 isRetracted "false" @default.
• W2555363527 magId "2555363527" @default.
• W2555363527 workType "article" @default.